Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fishbane, S.
Right arrow Articles by Mittal, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fishbane, S.
Right arrow Articles by Mittal, S. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1999) 14: 2595-2598
© 1999 European Renal Association-European Dialysis and Transplant Association

Invited Comments

Is there material hazard to treatment with intravenous iron?

Steven Fishbane, John K. Maesaka and Sanjeev K. Mittal

Winthrop-University Hospital, Mineola, NY, USA

Correspondence and offprint requests to: Steven Fishbane MD, 222 Station Plaza North, Suite 510, Mineola, NY 11501, USA.

We have been invited to write this article, exploring the question of whether we expose our patients to material hazard when we treat them with intravenous iron. It is a reasonable question to ask with any therapeutic agent, especially after a period in which the use of the agent has increased significantly. The answer to the question, to a degree, is dependent on the intended definition of the word material. We shall seek to utilize a working definition, in which material hazard is that which would outweigh any anticipated benefits that the treatment might confer. As such, we believe that there is not material hazard in the use of intravenous iron. Before exploring the risks of iron therapy, we will begin with a brief consideration of the benefits of intravenous iron for improving the anaemia therapy of haemodialysis patients.

Anaemia is one of the major causes of morbidity, mortality and . . . [Full Text of this Article]

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
G. Mircescu, L. Garneata, C. Capusa, and N. Ursea
Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients
Nephrol. Dial. Transplant., January 1, 2006; 21(1): 120 - 124.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
J. Q. Hudson and K. S. Schonder
Advances in Anemia Management in Chronic Kidney Disease
Journal of Pharmacy Practice, December 1, 2002; 15(6): 437 - 455.
[Abstract] [PDF]